STAT3 and breast cancer: In light of this, we developed a conventional de novo design and identified the essential output structures comprising imidazopyridine, pyrazole, pyrrole, and proposed a series of imidazopyridine-tethered pyrazolines (ITP) that could target STAT3 in breast cancer cells based on synthetic accessibility and chemical stability (Figure 1).